Inhibitory Effect of Clopidogrel, a P2Y₁₂ Receptor Antagonist, on Hematogenic Metastasis in B16-BL6 Mouse Melanoma Cells.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-05-01 DOI:10.21873/invivo.13936

Noriko Yoshikawa, Mingyu Xia, Kazuki Nakamura

{"title":"Inhibitory Effect of Clopidogrel, a P2Y12 Receptor Antagonist, on Hematogenic Metastasis in B16-BL6 Mouse Melanoma Cells.","authors":"Noriko Yoshikawa, Mingyu Xia, Kazuki Nakamura","doi":"10.21873/invivo.13936","DOIUrl":null,"url":null,"abstract":"Background/aim: The complex interactions between circulating platelets and tumor cells play important roles in tumor metastasis. Tumor cells can activate platelets by releasing mediators such as adenosine diphosphate (ADP). Treatments with anticoagulants have been shown to attenuate tumor metastasis. However, the role of ADP receptor P2Y12 in tumor cell metastasis has not been fully clarified.Materials and methods: In this study, highly metastatic B16-BL6 mouse melanoma cells were injected into the tail vein of mice as a model of hematogenic tumor metastasis to investigate the effects of P2Y12 antagonist clopidogrel on tumor metastasis.Results: A high dose (25 mg/kg) of clopidogrel weakly but significantly inhibited lung metastasis and increased both the time to hemostasis and blood loss in the tail tip-excision mouse model.Conclusion: Although it is necessary to consider increased bleeding as a side-effect, clopidogrel may be an effective antimetastatic drug.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1325-1330"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13936","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The complex interactions between circulating platelets and tumor cells play important roles in tumor metastasis. Tumor cells can activate platelets by releasing mediators such as adenosine diphosphate (ADP). Treatments with anticoagulants have been shown to attenuate tumor metastasis. However, the role of ADP receptor P2Y₁₂ in tumor cell metastasis has not been fully clarified.

Materials and methods: In this study, highly metastatic B16-BL6 mouse melanoma cells were injected into the tail vein of mice as a model of hematogenic tumor metastasis to investigate the effects of P2Y₁₂ antagonist clopidogrel on tumor metastasis.

Results: A high dose (25 mg/kg) of clopidogrel weakly but significantly inhibited lung metastasis and increased both the time to hemostasis and blood loss in the tail tip-excision mouse model.

Conclusion: Although it is necessary to consider increased bleeding as a side-effect, clopidogrel may be an effective antimetastatic drug.

查看原文本刊更多论文

P2Y12受体拮抗剂氯吡格雷对B16-BL6小鼠黑色素瘤细胞造血转移的抑制作用

背景/目的：循环血小板与肿瘤细胞之间复杂的相互作用在肿瘤转移中起重要作用。肿瘤细胞可以通过释放二磷酸腺苷（ADP）等介质激活血小板。抗凝治疗已被证明能减轻肿瘤转移。然而，ADP受体P2Y12在肿瘤细胞转移中的作用尚未完全阐明。材料与方法：本研究将高转移性B16-BL6小鼠黑色素瘤细胞注射至小鼠尾静脉，作为小鼠血源性肿瘤转移模型，研究P2Y12拮抗剂氯吡格雷对肿瘤转移的影响。结果：高剂量（25 mg/kg）氯吡格雷对小鼠尾尖切除模型肺转移有微弱但显著的抑制作用，并增加了止血时间和出血量。结论：虽然有必要考虑出血增加的副作用，但氯吡格雷可能是一种有效的抗转移药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.